课题基金 / 基金详情

Role of SENP1 in Prostate Cancer Pathogenesis

Role of SENP1 in Prostate Cancer Pathogenesis
SENP1 在前列腺癌发病机制中的作用
批准号:
7053800
负责人:
Tasneem Bawa-Khalfe
金额:
$4.88万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-01 至 2008-08-31

项目摘要

项目成果

Tasneem Bawa-Khalfe的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Our laboratory cloned the first human sentrin/SUMO-specific protease, SENP1. The isopeptidase activity of this enzyme deconjugates the posttranslation modification by SUMO (small ubiquitin-like modifier). Although its catalytic activity has been characterized, the biological significance of SENP1 remains unknown. Recently we observed that SENP1 enhances androgen receptor (AR)-dependent transcription. Numerous reports conclude that enhancement of AR activity promotes development of prostate cancer (PCa), the most frequently diagnosed carcinoma in males. In situ hybridization studies indicate an overexpression of SENP1 in pre-cancer and cancer lesions, but not normal prostate epithelia. Also, stable overexpression of SENP1 prompts PCa cell growth and transformation. Currently, it is unknown whether enhanced expression of SENP1 promotes prostate carcinogenesis; hence we propose to test whether induction of SENP1 regulates the development and progression of prostate cancer. Using an inducible system, the effect of SENP1 expression on proliferation of LNCaP cells and tumor growth in nude mice will be explored. Also, transgenic mice overexpressing SENP1 in the prostate will be evaluated for tumor formation and aggressiveness.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Constitutively Active SUMO Modified Androgen Receptors in Endocrine Resistant Breast Cancer
  • 批准号:
    10478966
  • 项目类别:
  • 资助金额:
    $34.88万
  • 财政年份:
    2021
  • 负责人:
    Tasneem Bawa-Khalfe
  • 依托单位:
Targeting Constitutively Active SUMO Modified Androgen Receptors in Endocrine Resistant Breast Cancer
  • 批准号:
    10299087
  • 项目类别:
  • 资助金额:
    $36.97万
  • 财政年份:
    2021
  • 负责人:
    Tasneem Bawa-Khalfe
  • 依托单位:
Targeting Constitutively Active SUMO Modified Androgen Receptors in Endocrine Resistant Breast Cancer
  • 批准号:
    10663317
  • 项目类别:
  • 资助金额:
    $34.88万
  • 财政年份:
    2021
  • 负责人:
    Tasneem Bawa-Khalfe
  • 依托单位:
Role of SENP1 in Prostate Cancer Pathogenesis
海外基金